Management of the Chronic Alcoholic Patient

1. General Approach

• Screen for alcohol use disorder severity, time of last drink, prior withdrawal history/seizures/DTs, and use a validated scale like CIWA-Ar to grade withdrawal severity (mild <8-10, moderate 10-19, severe/DT risk >20) - Katzung's Basic and Clinical Pharmacology; MDCalc CIWA-Ar.
• Look for and correct complications: hypoglycemia, electrolyte derangements (hypokalemia, hypomagnesemia, hypophosphatemia), hepatic dysfunction, GI bleeding, infection, pancreatitis, and trauma - these must be ruled out because they can mimic or worsen withdrawal (Symptom to Diagnosis, 4th ed.; Bradley and Daroff's Neurology).

• Give thiamine (100-300 mg, IV/IM) before any glucose-containing fluids in every chronic alcoholic - thiamine deficiency plus a glucose load can precipitate Wernicke's encephalopathy (Symptom to Diagnosis; Maudsley Prescribing Guidelines, 15th ed.). In assisted withdrawal or ongoing intake, Maudsley recommends 300 mg thiamine daily.
• Replace magnesium (a thiamine cofactor), potassium, and phosphate as renal function allows.
• Continue multivitamin/folate supplementation and address malnutrition.

• The core principle: substitute a long-acting sedative-hypnotic for alcohol, then taper gradually. Benzodiazepines are first-line because of their wide margin of safety (Katzung's, ch. 23).
  • Long-acting agents (diazepam, chlordiazepoxide): fewer doses needed, self-tapering active metabolites, but can accumulate in hepatic impairment.
  • Short-acting agents (lorazepam, oxazepam): converted to inactive metabolites, preferred in patients with significant liver disease.
• Dosing can be symptom-triggered (CIWA-Ar guided) or fixed-dose with tapering over several days.
• Mild withdrawal often needs no drug therapy beyond supportive care and monitoring.
• After acute control, benzodiazepines must be tapered slowly over days-to-weeks; full neurologic/sleep recovery can take months.

• DTs typically appear 48-72 hours after last drink: delirium, agitation, autonomic instability, fever, diaphoresis - a medical emergency requiring ICU-level monitoring, aggressive benzodiazepines, and fluid/electrolyte correction (Bradley and Daroff's; Katzung's).
• Refractory cases (not responding to escalating benzodiazepine doses) may need adjunctive phenobarbital, propofol, dexmedetomidine, or ketamine, per ICU protocols.

• Structured relapse-prevention program: naltrexone, acamprosate, or disulfiram as adjuncts; counseling/CBT; treatment of comorbid psychiatric disease and social supports.

2. Maximum Dose of IV Benzodiazepines in Alcohol Withdrawal

• In severe (CIWA-Ar >20) withdrawal, IV diazepam or lorazepam is given repeatedly every 10-15 minutes and reassessed.
• If a patient requires diazepam >120 mg cumulative (or a single dose >40 mg) without adequate control, this signals benzodiazepine-refractory withdrawal - move to ICU, add phenobarbital, and consider escalation protocols or alternative agents (propofol, ketamine, dexmedetomidine) rather than pushing benzodiazepines indefinitely.
• There is no absolute hard ceiling because tolerance in chronic heavy drinkers can be very high; dosing is titrated to sedation/RASS and respiratory status with continuous monitoring (telemetry, pulse oximetry) once doses climb this high, given the risk of respiratory depression.

3. Tackling Insomnia in the Chronic Alcoholic Patient

• Insomnia usually improves as the benzodiazepine taper controls overall withdrawal; a slightly higher evening dose of the taper regimen is often used rather than adding a separate hypnotic.
• Avoid stacking additional sedative-hypnotics on top of withdrawal benzodiazepines unless clearly needed, to limit respiratory depression risk.

• First-line: non-pharmacological. Sleep hygiene measures - fixed sleep/wake schedule, avoidance of caffeine, nicotine, and alcohol in the evening, avoiding naps, limiting screen/blue light exposure before bed, regular exercise - and Cognitive Behavioral Therapy for Insomnia (CBT-I), which has good evidence in this population and does not carry relapse risk (Goodman & Gilman's Pharmacological Basis of Therapeutics; Scott-Brown's Otorhinolaryngology; Bradley and Daroff's Neurology).
• Avoid other benzodiazepines/Z-drugs and OTC sedating antihistamines long-term in someone with alcohol use disorder given cross-dependence and relapse risk.
• Pharmacologic options with lower misuse potential when insomnia is persistent and impairing: sedating antidepressants such as trazodone, or gabapentin (which also has evidence for reducing both insomnia and craving in AUD), can be considered off-label; alpha-agonists or low-dose quetiapine are sometimes used in select patients, though evidence is mixed - these choices should be individualized with psychiatry/addiction medicine input.
• Treat comorbid depression/anxiety, which commonly perpetuate insomnia and drinking.
• Counsel explicitly against "self-medicating" with alcohol at bedtime - it fragments sleep architecture and worsens rebound insomnia (Goodman & Gilman's Pharmacological Basis of Therapeutics, "Barbiturates" section).

Clinical Summary

Most Probable Diagnosis

• Smoking chronically irritates the pharyngeal/nasal mucosa, sustaining reactive nodal drainage, and is itself a long-term risk factor that warrants cessation counseling.
• Night-shift work disrupts circadian rhythm and sleep, which can impair immune regulation and prolong recovery from recurrent upper respiratory inflammation - relevant context, not a primary diagnosis driver.

Management Plan

1. Reassurance, not emergency workup - given the benign imaging pattern and normal ESR/CRP, immediate biopsy or aggressive investigation is not indicated at this visit.
2. Treat the underlying triggers:
   • Allergic rhinitis: intranasal corticosteroid +/- second-generation antihistamine, allergen avoidance.
   • Pharyngitis: if there is an active/recurrent bacterial component (e.g., positive rapid strep or culture), treat with appropriate antibiotics (e.g., penicillin/amoxicillin); otherwise supportive care (saline gargles, hydration, avoid irritants) since most pharyngitis is viral.
   • ENT referral if pharyngitis is truly recurrent, to rule out chronic tonsillitis/adenoiditis as a persistent nodal stimulus.
3. Smoking cessation counseling - reduces chronic mucosal irritation and future head-neck cancer risk.
4. Sleep hygiene advice for night-shift work - regular sleep schedule, light exposure management, to support immune recovery.
5. No empiric antibiotics or steroids for the lymph nodes themselves - not indicated when imaging is reassuring and the patient is systemically well.
6. Scheduled follow-up (clinical +/- repeat USG in 4-6 weeks):
   • If nodes regress or stabilize -> confirms reactive/benign etiology, no further workup needed.
   • Escalate if any of the following develop: node fixed/hard/matted, size >1.5-2 cm, continued growth beyond 3 months, or systemic ("B") symptoms - fever, night sweats, unintentional weight loss. In that case obtain CBC with peripheral smear, EBV/CMV serology, HIV test, chest X-ray, and refer for excisional lymph node biopsy (preferred over FNA for suspected lymphoma, since architecture matters for subtyping).